SOUTHLAKE, Texas, Sept. 24, 2024 /PRNewswire/ — Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio, renal and metabolic diseases, today announced participation in the following upcoming investor conferences:…
